Results 111 to 120 of about 219,068 (308)
Cancer Management and Research, 2020 Bashan Zhang, Fei Li, Zinian Zhu, Aijiao Ding, Jintong Luo Department of Clinical Laboratory, Affiliated Dongguan People’s Hospital, Southern Medical University of Dongguan, Dongguan City, Guangdong Province, People’s Republic of ...
Zhang B, Li F, Zhu Z, Ding A, Luo J
doaj
Advanced Science, EarlyView.ZDHHC17 palmitoylates CDK4, which together with TRAF6‐mediated ubiquitination, drives cell cycle progression and immune surveillance, revealing a rational combination of CDK4 inhibitors with immune checkpoint blockers for ZDHHC17‐driven cancers. ABSTRACT Uncontrolled cell cycle progression is a hallmark of cancer, tightly regulated by both intrinsic ...
Zekang Wang +7 more
wiley +1 more source
NAFLD‐related hepatocellular carcinoma: The growing challenge
Hepatology, EarlyView., 2022 Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah +2 more
wiley +1 more source
Journal of Hepatocellular Carcinoma, 2023 Zhilu Yao,1,2,* Ning Liu,3,* Hui Lin,1 Yingqun Zhou2,4 1Department of Gastroenterology, Jingan District Zhabei Central Hospital, Shanghai, 200072, People’s Republic of China; 2Clinical Medical College of Shanghai Tenth People’s Hospital, Nanjing ...
Yao Z, Liu N, Lin H, Zhou Y
doaj
HO-1 is a favorable prognostic factor for HBV-HCC patients who underwent hepatectomy
, 2018 Chun-Nan Yeh,1 Ren-Chin Wu,2 Chi-Tung Cheng,1 Chun-Yi Tsai,1 Yau-Ren Chang,1 Ta-Sen Yeh,1 Tsung-Han Wu,1 Wei-Chen Lee,1 Kun-Chun Chiang3 1Department of Surgery, Liver Research Center, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333 ...
Tsai CY +8 more
core
, 2023 Qingyan Kong, Mengshi Yi, Fei Teng, Hang Li, Zheyu Chen Division of Hepatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People’s Republic of ChinaCorrespondence: Zheyu Chen, Division of ...
Li H, Kong Q, Chen Z, Yi M, Teng F
core
Tumor‐Infiltrating mregDCs Restrain Anti‐Tumor Immunity in Early Relapse HCC
Advanced Science, EarlyView.Tumor‐infiltrating mregDCs are regulated by the TNFR2‐non‐canonical NF‐κB axis, which is mediated by TNF‐α secreted by CD161+CD8+ T cells. These mregDCs recruit CD161+CD8+ T cells via the CCL20‐CCR6 axis, forming a positive feedback loop that enhances immunosuppression, promotes early recurrence of HCC, and further confirms TNFR2 as a key therapeutic ...
Zefan Zhang +13 more
wiley +1 more source
Hepatology, EarlyView., 2022 Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou +13 more
wiley +1 more source
Therapeutic strategies in liver cancer cells
, 2019 In present work, we also provide an overview of the biology of HCC, molecular mechanism of the disease, risk factors of HCC. We give the review of the most recent and future possible therapies of early and advanced stage of HCC ...
Sepahizia, Sina
core
Advanced Science, EarlyView.This study establishes a CT‐based radiomics framework to quantify intratumoral heterogeneity (ITH) in HNSCC. Using unsupervised clustering, tumor ROIs and VOIs are analyzed to calculate 2D/3D ITH scores. The score shows strong predictive value for prognosis and immunotherapy response, and is associated with tumor metabolism and immune microenvironment,
Xinwei Chen +15 more
wiley +1 more source